# WU-KONG28 (NCT05668988)

> A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05668988
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Dizal Pharmaceuticals
- Conditions: Non-small Cell Lung Cancer
- Interventions: sunvozertinib; Pemetrexed+carboplatin
- Enrollment: 324
- Primary outcome: Progression Free Survival (PFS) as assessed by Blinded Independent Central Review (BICR) per RECIST 1.1

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=wu-kong28-nct05668988